Clinical pharmacy and clinical trials

CPC-148 Table 1 adalimumab infliximab ustekinumab Lost to follow-up 5% (1/20) 23.5% (4/17) 22% (2/9) Continuing treatment 40% (8/20) 29.4% (5/17) 67% (6/9) Withdrawal/ Discontinuation by doctor 5% (1/20) 5.9% (1/17) 11% (1/9) Discontinuation due to good response 20% (4/20) – – Change of treatment 30% (6/20) 41.2% (7/17) – The causes of the discontinuation/change of treatment were: Abstract CPC-148 Table 2CPC-148 Table 2 adalimumab infliximab ustekinumab Lack of efficacy 27.2% (3/11) 25% (2/8) – Adverse reactions 18.2% (2/11) 37.5% (3/8) – Lack of response + adverse reactions 18.2% (2/11) 12.5% (1/8) – Lack of adherence – 25% (2/8) – Good response 36.4% (4/11) – – Other reasons – – 100% (1/1) Adverse reactions that caused withdrawal or change were: Abstract CPC-148 Table 3CPC-148 Table 3 Adalimumab Autoimmune hepatitis 25% (1/4) Asthenia and mood changes 25% (1/4) Psoriatic arthritis 25% (1/4) Pharyngitis and candidiasis 25% (1/4) Infliximab Acute infusion reactions 75% (3/4) Psoriatic arthropathy 25% (1/4) Conclusions The first biological in treatment-naive patients was 1st) adalimumab, 2nd) infliximab and 3rd) ustekinumab. Ustekinumab was the biological drug that achieved the best retention rate. Several patients discontinued their treatment with adalimumab because of good response, since it can be used in intermittent treatment schemes. Change in treatment was more frequent with infliximab, mainly because of infusion reactions. Ustekinumab was the only biological that didn’t cause adverse reactions that caused withdrawal or change. No conflict of interest. TrimeBuTine: a case of aBuse and possiBle dependence doi:10.1136/ejhpharm-2013-000276.606 A Guillermet, M Geneste, C Combe, H Hida. Hospital, Pharmacy, Valence Cedex, France Background Trimebutine has an agonist effect on digestive tract and brain mu, kappa, and delta opiate receptors. Purpose To describe a case report of an abuse and a possible dependence on trimebutine. Materials and Methods Medical record review and literature search about trimebutine dependence. Results A 46-year-old woman with a history of Chronic Intestinal Pseudo-Obstruction (CIPO) was prescribed amikacin and trimebutine in the hospital since 2011. Her gastroenterologist initially prescribed trimebutine at 100 mg intravenously three times a day, CPC-149 group.bmj.com on December 28, 2017 Published by http://ejhp.bmj.com/ Downloaded from